Rodman & Renshaw, page-31

Some terrific pathways in the short to medium term for CYP outlined in the past posts. Many thanks for that and the research -- right up to today.

With all the permutations going forward, eg. JV, licensing, royalyies, regional exclusivity, and of course, t/o, it's clear Wotton is earning his crust; just look at the sp =============================>

If a portion of revenue earning scenarios are realized then a cr may become moot. IF ther's a cr, if there's a retail component; seems like a good thing to invest in, albeit early days vis-a-vis clinical trials.

Once again, thanks! (I'd mention posters, but invariably I'd omit someone.)

OV